185 related articles for article (PubMed ID: 28542433)
1. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease.
Kugita M; Nishii K; Yamaguchi T; Suzuki A; Yuzawa Y; Horie S; Higashihara E; Nagao S
PLoS One; 2017; 12(5):e0177934. PubMed ID: 28542433
[TBL] [Abstract][Full Text] [Related]
2. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Gradilone SA; Huang B; Masyuk AI; Hogan MC; Torres VE; Larusso NF
Hepatology; 2013 Jul; 58(1):409-21. PubMed ID: 23172758
[TBL] [Abstract][Full Text] [Related]
3. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
Yoshihara D; Kugita M; Sasaki M; Horie S; Nakanishi K; Abe T; Aukema HM; Yamaguchi T; Nagao S
PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698
[TBL] [Abstract][Full Text] [Related]
5. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
Wang X; Harris PC; Somlo S; Batlle D; Torres VE
Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.
Torres VE; Sweeney WE; Wang X; Qian Q; Harris PC; Frost P; Avner ED
Kidney Int; 2004 Nov; 66(5):1766-73. PubMed ID: 15496147
[TBL] [Abstract][Full Text] [Related]
7. Effects of somatostatin analogs on glucose homeostasis in rats.
Schmid HA; Brueggen J
J Endocrinol; 2012 Jan; 212(1):49-60. PubMed ID: 21987782
[TBL] [Abstract][Full Text] [Related]
8. Dietary n-3 polyunsaturated fatty acids or soy protein isolate did not attenuate disease progression in a female rat model of autosomal recessive polycystic kidney disease.
Maditz KH; Oldaker C; Nanda N; Benedito V; Livengood R; Tou JC
Nutr Res; 2014 Jun; 34(6):526-34. PubMed ID: 25026920
[TBL] [Abstract][Full Text] [Related]
9. Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD.
Park F; Sweeney WE; Jia G; Akbulut T; Mueller B; Falck JR; Birudaraju S; Roman RJ; Avner ED
Am J Physiol Renal Physiol; 2009 Mar; 296(3):F575-82. PubMed ID: 19129252
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease.
Togawa H; Nakanishi K; Mukaiyama H; Hama T; Shima Y; Sako M; Miyajima M; Nozu K; Nishii K; Nagao S; Takahashi H; Iijima K; Yoshikawa N
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F511-20. PubMed ID: 21084407
[TBL] [Abstract][Full Text] [Related]
11. Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.
Sabbatini M; Russo L; Cappellaio F; Troncone G; Bellevicine C; De Falco V; Buonocore P; Riccio E; Bisesti V; Federico S; Pisani A
Am J Physiol Renal Physiol; 2014 May; 306(10):F1243-50. PubMed ID: 24647711
[TBL] [Abstract][Full Text] [Related]
12. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370
[TBL] [Abstract][Full Text] [Related]
13. Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats.
Kapoor S; Rodriguez D; Riwanto M; Edenhofer I; Segerer S; Mitchell K; Wüthrich RP
PLoS One; 2015; 10(4):e0125603. PubMed ID: 25927597
[TBL] [Abstract][Full Text] [Related]
14. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
[TBL] [Abstract][Full Text] [Related]
15. Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease.
Jia G; Kwon M; Liang HL; Mortensen J; Nilakantan V; Sweeney WE; Park F
Pediatr Nephrol; 2010 Jun; 25(6):1139-46. PubMed ID: 20229187
[TBL] [Abstract][Full Text] [Related]
16. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats.
Wang X; Zhang S; Liu Y; Spichtig D; Kapoor S; Koepsell H; Mohebbi N; Segerer S; Serra AL; Rodriguez D; Devuyst O; Mei C; Wüthrich RP
Kidney Int; 2013 Nov; 84(5):962-8. PubMed ID: 23715121
[TBL] [Abstract][Full Text] [Related]
17. Src inhibition ameliorates polycystic kidney disease.
Sweeney WE; von Vigier RO; Frost P; Avner ED
J Am Soc Nephrol; 2008 Jul; 19(7):1331-41. PubMed ID: 18385429
[TBL] [Abstract][Full Text] [Related]
18. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.
Yamaguchi T; Hempson SJ; Reif GA; Hedge AM; Wallace DP
J Am Soc Nephrol; 2006 Jan; 17(1):178-87. PubMed ID: 16319189
[TBL] [Abstract][Full Text] [Related]
19. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.
Holditch SJ; Schreiber CA; Harris PC; LaRusso NF; Ramirez-Alvarado M; Cataliotti A; Torres VE; Ikeda Y
Kidney Int; 2017 Sep; 92(3):657-668. PubMed ID: 28416225
[TBL] [Abstract][Full Text] [Related]
20. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.
Lager DJ; Qian Q; Bengal RJ; Ishibashi M; Torres VE
Kidney Int; 2001 Jan; 59(1):126-36. PubMed ID: 11135065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
